NCT01543854 - Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Acute Heart Failure

Interventions

DRUG

RLX030

Intravenous infusion of RLX030 over 20 hrs

DRUG

Placebo

Intravenous infusion of placebo over 20 hours

Trial Locations (20)

10117

Novartis Investigative Site, Berlin

17475

Novartis Investigative Site, Greifswald

25123

Novartis Investigative Site, Brescia

44137

Novartis Investigative Site, Dortmund

61231

Novartis Investigative Site, Bad Nauheim

99089

Novartis Investigative Site, Erfurt

121552

Novartis Investigative Site, Moscow

127644

Novartis Investigative Site, Moscow

192242

Novartis Investigative Site, Saint Petersburg

198013

Novartis Investigative Site, Saint Petersburg

198205

Novartis Investigative Site, S.-Petersburg

199106

Novartis Investigative Site, Saint Petersburg

634012

Novartis Investigative Site, Tomsk

650002

Novartis Investigative Site, Kemerovo

B1846BMF

Novartis Investigative Site, Buenos Aires

C1180AAX

Novartis Investigative Site, Caba

06120

Novartis Investigative Site, Halle

9713 GZ

Novartis Investigative Site, Groningen

04-628

Novartis Investigative Site, Warsaw

50-981

Novartis Investigative Site, Wroclaw